| Identification | Back Directory | [Name]
(3aR,4S,7aR)-Octahydro-4-hydroxy-4-[2-(3-methylphenyl)ethynyl]-1H-indole-1-carboxylic acid methyl ester | [CAS]
543906-09-8 | [Synonyms]
AFQ 056
GT0I9SV4F6
Mavoglurant
SureCN989279
CHEMBL3087515
UNII-GT0I9SV4F6
Mavoglurant, AFQ056
(3aR,4S,7aR)-Methyl 4-hydroxy-4-(2-M-tolylethynyl)-octahydroindole-1-carboxylate
UNII-GT0I9SV4F6; AFQ056; MAVOGLURANT; SURECN989279; GT0I9SV4F6; CHEMBL3087515; AFQ 056; AFQ-056
(3aR,4S,7aR)-Octahydro-4-hydroxy-4-[2-(3-methylphenyl)ethynyl]-1H-indole-1-carboxylic acid methyl ester
methyl (3aR,4S,7aR)-4-hydroxy-4-[2-(3-methylphenyl)ethynyl]-3,3a,5,6,7,7a-hexahydro-2H-indole-1-carboxylate
1H-Indole-1-carboxylic acid, octahydro-4-hydroxy-4-[2-(3-methylphenyl)ethynyl]-, methyl ester, (3aR,4S,7aR)- | [Molecular Formula]
C19H23NO3 | [MOL File]
543906-09-8.mol | [Molecular Weight]
313.39 |
| Chemical Properties | Back Directory | [Melting point ]
119 - 121°C | [Boiling point ]
476.3±45.0 °C(Predicted) | [density ]
1.21 | [storage temp. ]
2-8°C | [solubility ]
DMSO (Slightly), Methanol (Slightly) | [form ]
Solid | [pka]
12.75±0.20(Predicted) | [color ]
White to Off-White | [InChI]
InChI=1S/C19H23NO3/c1-14-5-3-6-15(13-14)8-11-19(22)10-4-7-17-16(19)9-12-20(17)18(21)23-2/h3,5-6,13,16-17,22H,4,7,9-10,12H2,1-2H3/t16-,17-,19-/m1/s1 | [InChIKey]
ZFPZEYHRWGMJCV-ZHALLVOQSA-N | [SMILES]
N1(C(OC)=O)[C@@]2([H])[C@]([H])([C@](O)(C#CC3=CC=CC(C)=C3)CCC2)CC1 |
| Hazard Information | Back Directory | [Uses]
Mavoglurant is a non-competitive metabotropic glutamate receptor 5 (mGlu5) receptor antagonist. | [Biological Activity]
Orally activepotent and selective mGluR5 antagonist.
AFQ056 (Mavoglurant) is an orally activepotent and selective antagonist of metabotropic glutamate receptor 5 (mGluR5). AFQ056 was investigated for treatment of fragile X syndrome and for Parkinsonμs disease. | [in vivo]
Mavoglurant (0.1-10 mg/kg; a single p.o.) inhibits the stress-induced hyperthermia (SIH) in a dose-dependent manner in mice[1].
Mavoglurant (9.4 mg/kg; a single p.o.) exhibits moderate oral bioavailability (32%), terminal half-life (2.9 h) and Cmax (plasma; brain) (950 pmol/mL; 3500 pmol/g)[1].
Mavoglurant (3.1 mg/kg; a single i.v.) exhibits terminal half-life (0.69 h), Cmax (plasma; brain) (3330 pmol/mL; 8400 pmol/g) and Tmax (≤0.08 h)[1]. | Animal Model: | Male OF1/IC mice[1] | | Dosage: | 0.1, 1, 10 mg/kg | | Administration: | A single p.o. administration | | Result: | Attenuated the stress-induced hyperthermia.
Was comparable to the positive control Chlordiazepoxide.
|
| Animal Model: | Male Sprague-Dawley rats (175-250 g)[1] | | Dosage: | 3.1 mg/kg for i.v.; 9.4 mg/kg for p.o. (Pharmacokinetic Analysis) | | Administration: | A single i.v. or p.o. administration | | Result: | P.o.: F=32%; T1/2=2.9 h; Tmax≤0.25 h.
I.v.: T1/2=0.69 h; Cmax (plasma/brain)=3330 pmol?mL-1/8400 pmol?g-1; Tmax≤0.08 h.
|
| [IC 50]
mGluR5: 30 nM (IC50) |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
| Company Name: |
Musechem
|
| Tel: |
+1-800-259-7612 |
| Website: |
www.musechem.com |
| Company Name: |
Twochem Co.Ltd.
|
| Tel: |
021-58111628 15800915896 |
| Website: |
cn.twochem.com |
|